145 related articles for article (PubMed ID: 33578778)
1. Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours.
Solano-Iturri JD; Echevarría E; Unda M; Loizaga-Iriarte A; Pérez-Fernández A; Angulo JC; López JI; Larrinaga G
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578778
[TBL] [Abstract][Full Text] [Related]
2. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy.
Larrinaga G; Valdivia A; Arrieta-Aguirre I; Solano-Iturri JD; Ugalde-Olano A; Loizaga-Iriarte A; Santos-Martín A; Pérez-Fernández A; Angulo JC; López JI
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338778
[TBL] [Abstract][Full Text] [Related]
3. Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours.
Solano-Iturri JD; Errarte P; Etxezarraga MC; Echevarria E; Angulo J; López JI; Larrinaga G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207686
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
5. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
6. Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma.
Ng KL; Ellis RJ; Samaratunga H; Morais C; Gobe GC; Wood ST
Transl Androl Urol; 2019 May; 8(Suppl 2):S123-S137. PubMed ID: 31236330
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
9. (Pro)renin Receptor Expression Increases throughout the Colorectal Adenoma-Adenocarcinoma Sequence and It Is Associated with Worse Colorectal Cancer Prognosis.
Beitia M; Solano-Iturri JD; Errarte P; Calvete-Candenas J; Loizate A; Etxezarraga MC; Sanz B; Larrinaga G
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31238566
[TBL] [Abstract][Full Text] [Related]
10. Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects.
Ouyang X; Xu C
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2595-2605. PubMed ID: 36153775
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in differentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma.
El-Shorbagy SH; Alshenawy HA
J Microsc Ultrastruct; 2017; 5(2):90-96. PubMed ID: 30023241
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of subtypes of renal cell carcinoma with contrast-enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li CX; Yan LX; Wang WP
Clin Hemorheol Microcirc; 2016 Oct; 63(4):361-371. PubMed ID: 26598999
[TBL] [Abstract][Full Text] [Related]
13. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cells within moderately differentiated head and neck cutaneous squamous cell carcinoma express components of the renin-angiotensin system.
Nallaiah S; Lee VMY; Brasch HD; de Jongh J; Schaijik BV; Marsh R; Tan ST; Itinteang T
J Plast Reconstr Aesthet Surg; 2019 Sep; 72(9):1484-1493. PubMed ID: 30528285
[TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade.
Mytsyk Y; Dutka I; Borys Y; Komnatska I; Shatynska-Mytsyk I; Farooqi AA; Gazdikova K; Caprnda M; Rodrigo L; Kruzliak P
Int Urol Nephrol; 2017 Feb; 49(2):215-224. PubMed ID: 27853915
[TBL] [Abstract][Full Text] [Related]
16. Differential radiologic characteristics of renal tumours on multiphasic computed tomography.
Ching BC; Tan HS; Tan PH; Toh CK; Kanesvaran R; Ng QS; Tan MH
Singapore Med J; 2017 May; 58(5):262-266. PubMed ID: 27090599
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
18. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy.
Zhang L; An XF; Ruan X; Huang DD; Zhou L; Xue H; Lu LM; He M
Front Physiol; 2017; 8():758. PubMed ID: 29056916
[No Abstract] [Full Text] [Related]
[Next] [New Search]
